Retinal Oxygen Metabolism and Haemodynamics in Patients With Multiple Sclerosis and History of Optic Neuritis.
Martin Kallab, Nikolaus Hommer, Andreas Schlatter...
https://pubmed.ncbi.nlm.nih.gov/34712117Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
ID03401879
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Led by Medical University of Vienna · Updated on 2025-05-23
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Multiple sclerosis (MS) is a condition affecting about 2.3 million people worldwide, typically diagnosed around age 30 and more common in women. It is identified by lesions in the central nervous system seen through clinical exams and MRI scans. This research aims to explore whether functional changes in the retina, beyond known anatomical changes, can be detected in MS patients by studying how the retina's blood flow responds to flicker light, reflecting the link between nerve activity and blood flow. The study compares patients with relapsing-remitting MS, including those with a history of optic neuritis, to healthy individuals matched by age and sex. Various devices will be used to measure retinal features: the Dynamic Vessel Analyzer (DVA) for vessel diameter and oxygen levels, Fourier Domain Doppler Optical Coherence Tomography (FDOCT) for blood flow, Optical Coherence Tomography (OCT) for nerve fiber and retinal thickness, and Optical Coherence Tomography Angiography (OCTA) for microvasculature. These assessments focus on both functional and structural retinal changes. Participants will undergo measurements on a single day, including flicker-induced retinal blood flow changes, vessel diameters, oxygen saturation, nerve fiber layer thickness, and specific flow signals. Researchers will monitor these parameters to understand retinal neurovascular function in MS. The study includes both patients and healthy volunteers, with all tests performed non-invasively. The total participation time is one day, with safety and data collected during this visit.
CONDITIONS
Brief Title
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Men and women aged over 18 years
- Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to clinical evaluation and McDonald criteria (revision 2010) for patients
- History of acute optic neuritis in one eye at least one year ago for patients
- Non-smokers
- Normal ophthalmic findings with ametropy less than 6 diopters
- Adequate visual acuity to allow participation in ocular blood flow measurements
- Stable doses of all medications for at least 30 days prior to inclusion if applicable
You will not qualify if you...
- Diagnosis of "possible MS" according to McDonald criteria for healthy subjects
- Severe medical conditions as judged by the investigator
- Untreated arterial hypertension
- History or family history of epilepsy
- Abnormalities preventing reliable eye measurements
- Family history of MS, optic neuritis, neuromyelitis optica, or related disorders for healthy subjects
- History of inflammatory or infectious central nervous system disease other than MS
- Best corrected visual acuity below 0.5 Snellen
- Ametropy of 6 diopters or higher
- Pregnancy or planned pregnancy
- Alcoholism or substance abuse
- Significant neurological disease other than MS considered relevant by investigator for patients
- History of neuromyelitis optica or related disorders for patients
- Presence or history of severe medical condition other than MS for patients
- History or family history of epilepsy
- Untreated arterial hypertension
- Abnormalities preventing reliable eye measurements
- Alcoholism or substance abuse for patients
- Pregnancy or planned pregnancy for patients
- Best corrected visual acuity less than 0.5 Snellen for patients
- Ametropy 6 diopters or greater for patients
- Significant neurological disease other than MS if relevant for patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Implementation
Duration - 1 day
Participants undergo retinal assessments using specialized imaging devices including Dynamic Vessel Analyzer, Fourier Domain Doppler Optical Coherence Tomography, Optical Coherence Tomography, and Optical Coherence Tomography Angiography to measure retinal blood flow, vessel diameters, oxygen saturation, and nerve fiber layer thickness.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria, Austria, 1090
Actively Recruiting
Loading map...
Research Team
G
Gerhard Garhöfer, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here